Sugi Predict

Sugi Predict / Compounds / SCHEMBL516378

SCHEMBL516378

SCHEMBL516378

CCOC(=O)C1(C)CCC(O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.38
▸ F10 P00742 2/20 0.37
▸ CES2 O00748 2/20 0.37
▸ CES1 P23141 2/20 0.37
▸ PRMT1 Q99873 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ OPRM1 P35372 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ OPRD1 P41143 2/20 0.33
▸ OPRK1 P41145 2/20 0.33
▸ FFAR3 O14843 1/20 0.33
▸ SLC22A1 O15245 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ PTPN2 P17706 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12549788 1.00 BRD4 (0.38) BRD4F10CES2CES1PRMT1
SCHEMBL663885 1.00 BRD4 (0.38) BRD4F10CES2CES1PRMT1
SCHEMBL19813356 0.89 F10 (0.39) BRD4F10CES2CES1PRMT1
SCHEMBL2289941 0.85 — —
SCHEMBL1908605 0.85 KDM4E (0.40) BRD4F10CES2CES1PRMT1
SCHEMBL18082673 0.85 KDM4E (0.40) BRD4F10CES2CES1PRMT1
SCHEMBL24313214 0.83 SMYD3 (0.39) BRD4F10CES2CES1PRMT1
SCHEMBL1282951 0.83 SMYD3 (0.39) BRD4F10CES2CES1PRMT1
SCHEMBL12549888 0.83 SMYD3 (0.39) BRD4F10CES2CES1PRMT1
SCHEMBL6745756 0.82 POLB (0.36) F10LMNAPOLBALDH1A1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
US-20240287086-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2024-08-29 — — US disclosed
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-02-13 — — US disclosed
EP-4069696-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-10-12 — — EP disclosed
US-11078233-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-06-10 — — US disclosed
WO-2021113479-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-06-10 — — WO disclosed
US-20200207809-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2020-07-02 — — US disclosed
US-10647744-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2020-05-12 — — US disclosed
US-RE47302-E1 Peptide epoxyketone immunoproteasome inhibitors ONYX THERAPEUTICS INC. (US) 2019-03-19 — — US disclosed
US-20110136735-A1 CYCLOHEXANE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-06-09 — — US disclosed
US-20110136735-A1 CYCLOHEXANE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-06-09 — — US disclosed
US-20110136735-A1 CYCLOHEXANE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-06-09 — — US disclosed
US-20110092547-A1 CHEMICAL COMPOUNDS 979 ASTRAZENECA AB (SE) 2011-04-21 — — US disclosed
US-20110092547-A1 CHEMICAL COMPOUNDS 979 ASTRAZENECA AB (SE) 2011-04-21 — — US disclosed
US-20110092547-A1 CHEMICAL COMPOUNDS 979 ASTRAZENECA AB (SE) 2011-04-21 — — US disclosed
CN-101827842-A Oxadiazole derivatives as dgat inhibitors ASTRAZENECA AB 2010-09-08 — — CN disclosed
EP-2190840-A2 CHEMICAL COMPOUNDS 979 AstraZeneca AB (SE) 2010-06-02 — — EP disclosed
WO-2009024821-A2 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
WO-2009024821-A2 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078233-B2 Tripeptide epoxy ketone protease inhibitors PREP, CTRL, ENPEP BRD4 1077/4885F10 1479/4885CES2 760/4885
US-20110092547-A1 CHEMICAL COMPOUNDS 979 DGAT1, DGAT2, ACAT2 BRD4 717/4885F10 2765/4885CES2 107/4885
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 BRD4 281/4885F10 2814/4885CES2 2885/4885
US-20200207809-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, CTRL, ENPEP BRD4 1077/4885F10 1479/4885CES2 760/4885
US-10647744-B2 Tripeptide epoxy ketone protease inhibitors PREP, CTRL, ENPEP BRD4 1077/4885F10 1479/4885CES2 760/4885
US-20240287086-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 BRD4 281/4885F10 2814/4885CES2 2885/4885
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 BRD4 281/4885F10 2814/4885CES2 2885/4885
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 BRD4 586/4885F10 675/4885CES2 1727/4885
US-20110136735-A1 CYCLOHEXANE DERIVATIVES AND USES THEREOF CYP3A5, CYP11B2, CNR2 BRD4 2036/4885F10 1561/4885CES2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.